Company / R&D per Share
Doximity R&D per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.48
FY2024
5-year range
$0.33 / $0.97
FY2020-FY2024
Trend
+12.6%
vs FY2023
Sector context
#87 of 103
Health Care
What the data says
Doximity's r&d per share of $0.48 is lower than 84% of companies in the Health Care sector (FY2024). R&D per Share has fluctuated over the past 6 years, ranging from $0.33 in FY2021 to $0.97 in FY2022.
Based on SEC 10-K filings.
0.48 in FY2024 with a 5-year CAGR of +3.9%.
Declined from $0.97 to $0.48 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.7%
- 5-Year CAGR
- +3.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 103This company $0.48 Sector average $2.13
▼
-77.5% below sector average
Key checks
Key Insights
- In FY2024, r&d per share increased 12.6% year-over-year.
- Ranks #87 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- Strong profit margin: 39.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.48 | +12.6% |
| FY2023 | $0.43 | -55.9% |
| FY2022 | $0.97 | +196.3% |
| FY2021 | $0.33 | -29.2% |
| FY2020 | $0.46 | +16.2% |
| FY2019 | $0.40 | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026